000125893 001__ 125893
000125893 005__ 20240228143339.0
000125893 0247_ $$2doi$$a10.1007/s00259-016-3346-0
000125893 0247_ $$2pmid$$apmid:26971788
000125893 0247_ $$2pmc$$apmc:PMC4906063
000125893 0247_ $$2ISSN$$a0340-6997
000125893 0247_ $$2ISSN$$a1432-105X
000125893 0247_ $$2ISSN$$a1619-7070
000125893 0247_ $$2ISSN$$a1619-7089
000125893 0247_ $$2altmetric$$aaltmetric:6192788
000125893 037__ $$aDKFZ-2017-02017
000125893 041__ $$aeng
000125893 082__ $$a610
000125893 1001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b0$$eFirst author$$udkfz
000125893 245__ $$aIntra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer.
000125893 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2016
000125893 3367_ $$2DRIVER$$aarticle
000125893 3367_ $$2DataCite$$aOutput Types/Journal article
000125893 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524733326_26429
000125893 3367_ $$2BibTeX$$aARTICLE
000125893 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125893 3367_ $$00$$2EndNote$$aJournal Article
000125893 520__ $$aMulti-parametric magnetic resonance imaging (MP-MRI) is currently the most comprehensive work up for non-invasive primary tumor staging of prostate cancer (PCa). Prostate-specific membrane antigen (PSMA)-Positron emission tomography-computed tomography (PET/CT) is presented to be a highly promising new technique for N- and M-staging in recurrent PCa-patients. The actual investigation analyses the potential of (68)Ga-PSMA11-PET/CT to assess the extent of primary prostate cancer by intra-individual comparison to MP-MRI.In a retrospective study, ten patients with primary PCa underwent MP-MRI and PSMA-PET/CT for initial staging. All tumors were proven histopathological by biopsy. Image analysis was done in a quantitative (SUVmax) and qualitative (blinded read) fashion based on PI-RADS. The PI-RADS schema was then translated into a 3D-matrix and the euclidian distance of this coordinate system was used to quantify the extend of agreement.Both MP-MRI and PSMA-PET/CT presented a good allocation of the PCa, which was also in concordance to the tumor location validated in eight-segment resolution by biopsy. An Isocontour of 50 % SUVmax in PSMA-PET resulted in visually concordant tumor extension in comparison to MP-MRI (T2w and DWI). For 89.4 % of sections containing a tumor according to MP-MRI, the tumor was also identified in total or near-total agreement (euclidian distance ≤1) by PSMA-PET. Vice versa for 96.8 % of the sections identified as tumor bearing by PSMA-PET the tumor was also found in total or near-total agreement by MP-MRI.PSMA-PET/CT and MP-MRI correlated well with regard to tumor allocation in patients with a high pre-test probability for large tumors. Further research will be needed to evaluate its value in challenging situation such as prostatitis or after repeated negative biopsies.
000125893 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000125893 588__ $$aDataset connected to CrossRef, PubMed,
000125893 650_7 $$2NLM Chemicals$$aGlu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))
000125893 650_7 $$2NLM Chemicals$$aOligopeptides
000125893 650_7 $$09G34HU7RV0$$2NLM Chemicals$$aEdetic Acid
000125893 7001_ $$aSterzing, F.$$b1
000125893 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, H. P.$$b2$$udkfz
000125893 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, T.$$b3$$udkfz
000125893 7001_ $$0P:(DE-HGF)0$$aMier, W.$$b4
000125893 7001_ $$aRius, M.$$b5
000125893 7001_ $$0P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aAfshar-Oromieh, A.$$b6$$udkfz
000125893 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, K.$$b7$$udkfz
000125893 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, J.$$b8$$udkfz
000125893 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, U.$$b9$$udkfz
000125893 7001_ $$aKratochwil, C.$$b10
000125893 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-016-3346-0$$gVol. 43, no. 8, p. 1400 - 1406$$n8$$p1400 - 1406$$tEuropean journal of nuclear medicine and molecular imaging$$v43$$x1619-7089$$y2016
000125893 909CO $$ooai:inrepo02.dkfz.de:125893$$pVDB
000125893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000125893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000125893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000125893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000125893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000125893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000125893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000125893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000125893 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000125893 9141_ $$y2016
000125893 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125893 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125893 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125893 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000125893 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000125893 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000125893 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125893 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125893 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125893 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125893 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125893 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000125893 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000125893 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000125893 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x1
000125893 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x2
000125893 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x3
000125893 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x4
000125893 980__ $$ajournal
000125893 980__ $$aVDB
000125893 980__ $$aI:(DE-He78)C060-20160331
000125893 980__ $$aI:(DE-He78)E060-20160331
000125893 980__ $$aI:(DE-He78)E010-20160331
000125893 980__ $$aI:(DE-He78)E050-20160331
000125893 980__ $$aI:(DE-He78)E030-20160331
000125893 980__ $$aUNRESTRICTED